Description

Polcortolon (ramipril) tablets 4 mg. №50

Ingredients

Active ingredient: Ramipril 4 mg per tablet.

Dosage

Recommended dosage: The usual dose is 2.5 mg to 20 mg per day, depending on the condition being treated.

Indications

Indicated for: Hypertension, heart failure, and to improve survival after a heart attack.

Contraindications

Do not use if: Allergic to ramipril, pregnant, or have a history of angioedema.

Directions

Administration: Take the tablet by mouth with or without food as directed by your doctor.

Scientific Evidence

Ramipril, the active ingredient in Polcortolon tablets, is an ACE inhibitor that has been extensively studied for its efficacy in managing hypertension and heart failure. Clinical trials have demonstrated its ability to reduce blood pressure, improve cardiac function, and increase survival rates in patients with cardiovascular conditions. One study published in the New England Journal of Medicine showed a significant reduction in the risk of cardiovascular events with ramipril therapy.

Additional Information

It is important to regularly monitor blood pressure and kidney function while taking ramipril. Common side effects may include dizziness, cough, and elevated potassium levels. Consult your healthcare provider for personalized recommendations and to discuss any concerns.

Pharmacological Effects

Ramipril works by inhibiting the angiotensin-converting enzyme (ACE), which plays a crucial role in regulating blood pressure and fluid balance in the body. By blocking ACE, ramipril helps dilate blood vessels, reduce the workload on the heart, and improve overall cardiovascular function. This mechanism of action makes ramipril an effective medication for managing hypertension and heart-related conditions.

Clinical Trials and Comparative Effectiveness

Several clinical trials have compared the effectiveness of ramipril with other antihypertensive medications, showing favorable outcomes in terms of blood pressure control, cardiovascular risk reduction, and overall patient outcomes. A meta-analysis published in JAMA Cardiology highlighted the benefits of ACE inhibitors like ramipril in reducing the incidence of heart failure and improving long-term prognosis in patients with cardiovascular diseases.